In WT TP53 AML, the overexpression of MDM2 and MDMX causes the inactivation of TP53, providing a very strong rationale for the use of MDM2/MDMX inhibitors in synergistic strategies and as venetoclax resensitizing agents [67]. This evidence concerns the gene MDM2 and acute myeloid leukemia.